- Home
- PCRX vs THFF Comparison
PCRX vs THFF Comparison
Compare PCRX & THFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- THFF
- Stock Information
- Founded
- PCRX 2006
- THFF 1984
- Country
- PCRX United States
- THFF United States
- Employees
- PCRX N/A
- THFF N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- THFF Major Banks
- Sector
- PCRX Health Care
- THFF Finance
- Exchange
- PCRX Nasdaq
- THFF Nasdaq
- Market Cap
- PCRX 1.2B
- THFF 625.8M
- IPO Year
- PCRX 2011
- THFF N/A
- Fundamental
- Price
- PCRX $24.02
- THFF $54.19
- Analyst Decision
- PCRX Buy
- THFF Buy
- Analyst Count
- PCRX 9
- THFF 2
- Target Price
- PCRX $29.89
- THFF $56.50
- AVG Volume (30 Days)
- PCRX 526.9K
- THFF 54.1K
- Earning Date
- PCRX 07-29-2025
- THFF 07-22-2025
- Dividend Yield
- PCRX N/A
- THFF 3.75%
- EPS Growth
- PCRX N/A
- THFF N/A
- EPS
- PCRX N/A
- THFF 4.63
- Revenue
- PCRX $702,772,000.00
- THFF $215,577,000.00
- Revenue This Year
- PCRX $7.54
- THFF $29.97
- Revenue Next Year
- PCRX $10.78
- THFF $2.84
- P/E Ratio
- PCRX N/A
- THFF $11.75
- Revenue Growth
- PCRX 3.08
- THFF 9.26
- 52 Week Low
- PCRX $11.16
- THFF $35.62
- 52 Week High
- PCRX $29.33
- THFF $54.63
- Technical
- Relative Strength Index (RSI)
- PCRX 36.83
- THFF 64.58
- Support Level
- PCRX $23.85
- THFF $51.91
- Resistance Level
- PCRX $25.16
- THFF $54.63
- Average True Range (ATR)
- PCRX 0.79
- THFF 1.18
- MACD
- PCRX -0.12
- THFF 0.23
- Stochastic Oscillator
- PCRX 8.20
- THFF 91.04
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.